Merz Therapeutics’ Post

Exemplifying a future-focused approach in the industry, Gerresheimer illustrates the profound intersection of business strategy and sustainability. Our commitment to long-term impact transcends the bottom line, setting a benchmark for resolute leadership. It's initiatives like these that redefine corporate responsibility. #Leadership #Sustainability #Innovation 🌱🌍💼

A recent survey from our colleagues at Cytiva and the Financial Times found that while sustainability is integral to success, some pharma companies are having a hard time achieving their green initiatives. Let’s explore this topic further. As our team members and partners already know, advancing sustainability within the industry is a core tenet of AustinPx and a personal passion among our leadership. Among more than 800 biopharma executives surveyed, more than half of the participating companies have experienced large boosts in brand reputation, profit, share price, revenue, and ability to attract talent, all because of their effort to practice sustainability. The survey concluded that companies must continue to place sustainability at the top of their agenda and then communicate this initiative internally and externally. At AustinPx, we want to continue this important conversation by demonstrating how sustainability drives value and innovation across the industry. For our team, KinetiSol’s superior performance to spray drying in manufacturing amorphous dispersions demonstrates how a greener, innovative alternative can not only minimize hazardous waste and emissions, but also significantly reduces timelines and total costs. Read about the survey results here: https://lnkd.in/guhFX7jm #amorphousdispersion #SustainablePharma #InnovationForChange #KinetiSol

On World Environment Day, we reaffirm our commitment to safeguarding our planet for generations to come. The medical and pharmaceutical industries face a number of challenges in reducing their environmental impact, but external support can help you join the dots across a product's ecosystem. Our expert Sustainability Lab team understands the challenges of adopting sustainable product systems within the existing constraints of medical and healthcare product development – from reuse to recycling, new materials to digital interventions. We have the ability to play a critical role in supporting clients to minimise environmental impact.
 From the start of a programme, we utilise expert thinking to embed a sustainability mindset alongside our commercial one, into our innovation and design activities. This gives sustainable, circular and regenerative solutions the best chance of success in the real world – meaning big ideas are put into action for the decade ahead. As part of the SteriPack Group, sustainability is at the forefront of everything we do, as we remain dedicated to developing innovative and sustainable solutions for the medical device and pharmaceutical industries.
 Find out more about our Sustainability Lab here: https://lnkd.in/egG9XAQp 
#WorldEnvironmentDay #Sustainability #ESG

Cytiva Report: Responsible for an estimated 13% more emissions than the automotive industry, biopharma companies are making sustainability a priority. Sustainability currently sits at the heart of biopharma organizations’ strategies, with 62% of our survey respondents noting it’s a top business priority for the next five years. It’s no secret that there are a number of other factors facing the industry right now, so it’s encouraging to see sustainability as a focus area alongside these challenges. And our findings show that companies have good reasons to focus on sustainability: 63% see it as imperative to differentiation and business growth, and biopharma is already reaping some of the benefits. As Matthias Berninger, Executive Vice President of Public Affairs, Science, Sustainability and HSE at Bayer, notes, “When we decided to create measurable targets in this area, it led to business decisions that ultimately paid off.” About four out of 10 respondents (42%) have improved their relationships with regulators because of sustainability efforts. Companies have also found it easier to attract investment and win new business. #sustainability #cytiva #biopharma Continue reading here: https://lnkd.in/gDjjtQdM

WBCSD – World Business Council for Sustainable Development in partnership with GSK is convening the pharma sector including AstraZeneca, Bayer, Novartis, Novo Nordisk, Roche and Takeda, to develop an additional tool to the Roadmaps to Nature Positive series, focusing on the pharmaceutical sector. With support from PwC UK, the Roadmap will support companies to:  👉Identify the key sector impacts, dependencies and priority actions for nature 👉Prepare for the emerging nature-related corporate performance and accountability frameworks 👉Drive collaborative action to address shared challenges and maximize impact and scale Claire Lund, VP, Sustainability, GSK: “Action on nature matters for health, climate and long-term business success. That’s why we’ve made a commitment, alongside our net zero goal, to contribute to a nature-positive world. This includes reducing our value chain impacts on nature, as well as investing in the protection and restoration of nature. Collaboration is key to making progress so we’re pleased to be coming together with our sector peers to identify and accelerate the priority actions for nature that we can take together.” Diane Holdorf, Executive VP, WBCSD: “WBCSD is building on its extensive business guidance for ‘how-to’ assess and manage nature-related risks and define strategies to accelerate business performance and accountability in support of nature-positive outcomes. This latest Roadmap will facilitate the pharmaceutical sector preparedness to act on nature.” Carrie Scott, Head, Sustainability & ESG Office, Novartis: "The health of our planet directly influences human health. As we continue to deliver on our environmental sustainability commitments, we recognize that navigating towards a nature positive future requires diligence and collective effort. At Novartis, we're excited about the prospect of working in partnership with our peers to identify priority actions and progress effectively in this journey.” Kristie Boissonneault, ASP, Nature Lead, Takeda: "Taking action to protect nature is vital for health, climate resilience, and sustainable business success. Takeda is dedicated to contributing to a nature-positive world by reducing our environmental impacts, investing in the conservation and restoration of natural resources, and collaborating with our industry peers to identify and implement key actions for nature. Through these efforts, we aim to support the health of both people and the planet." Liz Chatwin, VP, Global Sustainability, AstraZeneca: “Achieving greater harmony between nature and society is critical for the health of people and planet. AstraZeneca is committed to taking action on our key impacts and dependencies on nature across our value chain. We’re also pleased to be collaborating with our peers to co-develop The Roadmap for the pharmaceutical sector, harnessing the power of collective action.”  #Sustainability #WBCSD #PwCUK #AstraZeneca #Bayer #GSK #Novartis #NovoNordisk #Roche #Takeda

The publication of this year’s Sustainability Report fills me with huge pride for Merck Healthcare. Firstly, because of how much has been achieved since we established our three clear sustainability goals in 2020, in line with the UN Sustainable Development Goals (#SDGs). We have not only implemented environmentally progressive processes and projects across our Healthcare business, but also continue to dedicate ourselves to human progress, as an example, by strengthening our patient access strategy in low- and middle-income countries, ensuring that all patients across the globe can benefit from our medicines. Secondly, I am proud of the commitment that our teams show as we look to the future of our sustainability strategy. We continue to set ambitious targets that will impact society for good, notably our goal of eliminating schistosomiasis as a public health problem by 2030. Our success lies in the focus and capabilities of our teams as well as our collaboration with the many external partners and organizations that we are proud to work with, enabling us to embed sustainable change throughout Merck and beyond.   Read the full report here: https://lnkd.in/epm7Fsfh Merck Group #Sustainability #TeamMerck

Making strides in sustainability is challenging. We surveyed 800 pharma and biopharma executives across 18 countries to learn more about the state of sustainability in biopharma. The Sustainability Review covers the industry’s sustainability progress in improving sustainability and the impact of prioritizing environmental initiatives. Dive into some of the findings here: https://cytiva.link/7fnal.

Leading the way in sustainability: I'm excited to share how in AstraZeneca we're driving significant progress in sustainable practices in partnership with EcoVadis and our suppliers. Join us on this journey by exploring our case study below: #EcoVadisSuccessStory #Collaboration #DEI #SustainablePractices

Sustainability is rising to the top of the global agenda as regulations are evolving and investors, customers, and talent demand more transparency from companies on the topic. GEN highlighted insights from our 2024 Global Biopharma Sustainability Review. Check out these insights now.

Sustainability is rising to the top of the global agenda as regulations are evolving and investors, customers, and talent demand more transparency from companies on the topic. GEN highlighted insights from our 2024 Global Biopharma Sustainability Review. Check out these insights now.